Antiplatelet agents

All categories
DBCAT000149Therapeutic category

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. A DrugBank category of 71 drugs. 22 of them are approved.

Also known as
Agents with Antiplatelet Properties · Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.) · Agents, Antiplatelet · Aggregation Inhibitors, Platelet · Antagonists, Blood Platelet
Drugs

and 46 more with a free account

What you can answer from here — as of September 25, 2018

71DrugsEach linked to its full drug card
Sign in
138Drug targetsEvery drug–target pair in the class, with bond type
Sign in
6,824Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
19Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Antiplatelet agents share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In